Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?

Cardoso, Fátima; Leo, Angelo Di; Lohrisch, Caroline; Bernard, Chantal; Ferreira, Fábio Oliveira; Piccart, Martine

doi:10.1093/annonc/mdf101

Cited by 131 publications

(89 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2 Once metastases are detected, the median survival time is approximately 18-24 months. 3 Recent estimates show that the 5-year survival rate for women with metastatic breast cancer (MBC) is 27%. 1 In 2006, it was estimated that close to 50,000 women across North America died from MBC, and that more than 400,000 women worldwide will die annually of this disease.…”

Section: ■■ Methods Model Structure and Calculationsmentioning

confidence: 99%

Budget Impact Analysis of Ixabepilone Used According to FDA Approved Labeling in Treatment-Resistant Metastatic Breast Cancer

Ho¹,

Zhang²,

Todorova³

et al. 2009

JMCP

View full text Add to dashboard Cite

incremental cost PMPM was $0.002 for each of the 3 years. The estimated incremental cost PMPM for the ATC-p population was $0.003 for year 1 and $0.004 for both year 2 and year 3. In sensitivity analyses, the PMPM impact varied between -$0.01 and $0.02 over the 3-year period. The model was most sensitive to the cost of ixabepilone.CONCLUSION: Given the poor prognosis and limited number of treatment options for patients with MBC, the need for widespread coverage of ixabepilone in accordance with FDA-approved indications can clearly be established. Assuming that ixabepilone is used only for its currently labeled indications, both the number of patients eligible for ixabepilone treatment and the expected budget impact of covering ixabepilone for this group of patients are relatively small. ABSTRACT BACKGROUND: Breast cancer is one of the most common forms of cancer in the United States, with approximately 10% of newly diagnosed patients presenting with metastatic disease. Limited therapy options make the successful treatment of metastatic breast cancer (MBC) difficult. Current treatment options include drugs belonging to the classes of anthracyclines and taxanes as well as the drug capecitabine. Resistance to these classes of drugs is often acquired, thus highlighting the need for newer agents capable of managing treatment resistant disease. Ixabepilone is an antineoplastic agent from the epothilone class that was FDA-approved in October 2007 for the treatment of metastatic or locally advanced breast cancer. The FDA-approved indications for ixabepilone specify (a) use of ixabepilone in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer after (resistance to) treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated; and (b) ixabepilone as a monotherapy for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to an anthracycline, a taxane, and capecitabine.

show abstract

Section: ■■ Methods Model Structure and Calculationsmentioning

confidence: 99%

Budget Impact Analysis of Ixabepilone Used According to FDA Approved Labeling in Treatment-Resistant Metastatic Breast Cancer

Ho¹,

Zhang²,

Todorova³

et al. 2009

JMCP

View full text Add to dashboard Cite

show abstract

“…Le taux de réponse en troisième ligne ou plus est considéré comme très faible (24), pour un bénéfice très bref, et le rapport efficacité/toxicité devrait être pris en compte (24,25). La question se posera alors de l'arrêt de la chimiothérapie et du passage aux soins palliatifs vrais, lorsque le bénéfice escompté sera inférieur aux inconvénients, en maintenant avec la malade une communication adaptée et rassurante (26).…”

Section: Traitements En Phase Palliative Activeunclassified

Soins palliatifs: peut-on parler de qualité de vie en phase métastatique?

Kerbrat

Botton

2007

Cancer Du Sein Avancé

View full text Add to dashboard Cite

Poser la question sous cette forme paraît impliquer une réponse évidente. L'amélioration de la qualité de vie est un objectif premier de l'activité médi-cale, quelle qu'en soit sa situation : prévention, dépistage, thérapeutique adjuvante ou palliative ; le patient doit pouvoir espérer, sinon tirer, un bénéfice du geste entrepris. L'évaluation des avantages, quels qu'ils soient, doit être contrebalancée par celle des inconvénients.En situation métastatique d'un cancer du sein, cette question peut paraître curieuse dans la mesure où, sauf cas exceptionnel, la patiente ne peut espérer guérir, avec une survie en moyenne inférieure à 3 ans, même si 10 % des malades peuvent espérer une survie supérieure à 10 ans (1). Durant cette période, plusieurs traitements spécifiques, systémiques -chimiothérapie, hormonothérapie, et traitements ciblés -ou locorégionaux -chirurgie, radiothérapie, radiologie interventionnelle -, mais aussi non spécifiques -bisphosphonates, antalgiques, corticoïdes, etc. -seront utilisés.À chaque instant le thérapeute devra, pour la patiente et avec elle, évaluer le rapport coût/bénéfice. Après une réflexion sur les objectifs du traitement, et la définition et la mesure de la qualité de vie, nous séparerons artificiellement deux phases durant cette période, de longueur très variable, une phase « palliative active » où une thérapeutique anticancéreuse sera employée, puis une phase « palliative terminale » proprement dite, avec parfois une frontière difficile à définir ( fig. 1) (2). Objectifs des traitementsIls ont été encore récemment définis en rappelant qu'actuellement le cancer du sein métastatique reste une maladie incurable. Pour le groupe allemand

show abstract

“…Según la literatura, estudios realizados en 1987 han reportado una sobrevida de 24 meses, con una supervivencia a los 5 años de un 40% en pacientes portadores de metástasis óseas 3,7 . Estudios posteriores en 2002, reportaron una sobrevida media de 18 a 24 meses, con una supervivencia a los 5 años del 20% 8 , y si la metástasis está confinada sólo a esqueleto, se estimó una sobrevida promedio de 6 años 9 . El sitio más común de metástasis es la columna vertebral (63%), seguido por pelvis, esternón, costillas, cráneo y huesos largos 4,9 .…”

Section: Introductionunclassified

Sobrevida de pacientes con cáncer de mama y metástasis ósea

et al. 2013

Rev Chil Cir

View full text Add to dashboard Cite

Survival of patients with breast cancer and bone metastasisIntroduction: Breast cancer is an important cause of death among female cancer in Chile. It metastasizes to any part of the body, being bone the first area of dissemination in 26-50% of cases and being found in 75% of patients dead from this cause. A median survival of 18 to 24 months is reported, and a probability of surviving 5 years of 20%. Therefore the objective of this study is to determine the difference of median survival depending on the presence of bone metastasis. Methods: A retrospective cohort study was conducted with 822 patients diagnosed with breast cancer between 2003 and 2010. The exposed cohort had scintigraphicly diagnosed bone metastasis, and the control group had no bone metastasis. Results: 8.88% of 822 patients, had bone metastasis. Those with bone metastasis had a mortality of 74%, and in the group with no bone metastasis, 16.69% died (p < 0.01). The median survival of patients with no metastasis was 44.3 months , and with metastasis was of 35 (IQR 18.6-46.1) (p < 0.01). With bone metastasis, over 48 months survival was 30.6%; and over 84 months 14.8%. Without bone metastasis, above 84 months, 78.51% survived (p < 0.01). Discussion and Conclusions: The difference between the two groups, considering global survival, is significant and implies an important decrease in survival and quality of life; the result obtained also differs from those reported in literature and it makes us reflect on the importance to consider bone metastasis not as a terminal event.

show abstract

Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?

Cited by 131 publications

References 58 publications

Budget Impact Analysis of Ixabepilone Used According to FDA Approved Labeling in Treatment-Resistant Metastatic Breast Cancer

Budget Impact Analysis of Ixabepilone Used According to FDA Approved Labeling in Treatment-Resistant Metastatic Breast Cancer

Soins palliatifs: peut-on parler de qualité de vie en phase métastatique?

Sobrevida de pacientes con cáncer de mama y metástasis ósea

Contact Info

Product

Resources

About